Metabolic control in newly kidney transplanted insulin-dependent diabetics: improvement by insulin pump treatment (CSII)
- PMID: 2969910
- DOI: 10.1016/s0891-6632(87)80061-2
Metabolic control in newly kidney transplanted insulin-dependent diabetics: improvement by insulin pump treatment (CSII)
Abstract
Management of glucose homeostasis in newly kidney transplanted insulin-dependent diabetic patients is difficult. To examine whether continuous subcutaneous insulin infusion (CSII) could reverse this problem, six consecutive kidney-transplanted Type I diabetic patients either proceeded with conventional insulin therapy (CIT) or were changed to CSII beginning on the third postoperative day. After a mean of 13 days, the insulin administration mode was changed from CIT to CSII (n = 3) or from CSII to CIT (n = 3), and continued for a further 15 days. Mean blood glucose calculated on the basis of four daily measurements (8.00, 12.00, 17.00, 22.00 h) during the study periods was significantly lower during CSII (8.0 +/- 0.4 mmol/l, mean +/- SEM) than on CIT (11.0 +/- 0.6 mmol/l; p less than 0.005). Moreover, the variability of blood glucose expressed as the M-value was lower during the pump treatment compared to CIT (p less than 0.001), while the number of blood glucose values below 3.0 mmol/l was similar (3.8 vs. 4.4%). Diurnal metabolic and hormonal profiles were twice determined on each regimen with 2 hourly sampling. Glycemic control was again found to be improved during CSII therapy as compared to CIT (p less than 0.01 or 0.05 less than p less than 0.10). Moreover, insulin pump treatment resulted in a significant reduction of two major intermediary metabolites, lactate and glycerol (p less than 0.05 and p less than 0.01, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy.Diabetes Care. 1986 May-Jun;9(3):221-7. doi: 10.2337/diacare.9.3.221. Diabetes Care. 1986. PMID: 3525052 Clinical Trial.
-
Metabolic effects of continuous subcutaneous insulin infusion: evidence that a rise and fall of portal vein insulin concentration with each major meal facilitates post-absorptive glycemic control.Clin Invest Med. 1988 Jun;11(3):167-86. Clin Invest Med. 1988. PMID: 3042215 Clinical Trial.
-
Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement.Diabetes Res. 1990 Dec;15(4):185-90. Diabetes Res. 1990. PMID: 2132407 Clinical Trial.
-
Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.Diabetes Care. 2002 Mar;25(3):593-8. doi: 10.2337/diacare.25.3.593. Diabetes Care. 2002. PMID: 11874953 Review.
-
[Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].Przegl Lek. 2005;62(1):49-53. Przegl Lek. 2005. PMID: 16053222 Review. Polish.
Cited by
-
Continuous Insulin Therapy to Prevent Post-Transplant Diabetes Mellitus: A Randomized Controlled Trial.Kidney Med. 2024 Jun 21;6(8):100860. doi: 10.1016/j.xkme.2024.100860. eCollection 2024 Aug. Kidney Med. 2024. PMID: 39157193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical